Medical Condition

brain metastases

Total Trials

14

Recruiting Now

14

Trial Phases

Phase 1, Phase 2, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for brain metastases sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — brain metastases Clinical Trials

How many clinical trials are currently recruiting for brain metastases?

ClinicalMetric currently tracks 14 actively recruiting clinical trials for brain metastases, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 14. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for brain metastases?

brain metastases research spans Phase 1 (5 trials), Phase 2 (6 trials), Phase 3 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a brain metastases clinical trial?

Eligibility criteria for brain metastases trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Phase 3

Top Sponsors

Baptist Health South Florida 2 trials

Sun Yat-sen University 2 trials

Dana-Farber Cancer Institute 1 trial

Hadassah Medical Organization 1 trial

Institut de Recherches Internationales Servier 1 trial

Recruiting Clinical Trials

NCT04115254

Recruiting

Stereotactic Magnetic Resonance Guided Radiation Therapy

Dana-Farber Cancer Institute

View Trial →

NCT06048094 Phase 1

Recruiting

18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery

Baptist Health South Florida

View Trial →

NCT05033691

Recruiting

A Study to Evaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain Metastases

Hadassah Medical Organization

View Trial →

NCT05554302 Phase 2

Recruiting

Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis

Baptist Health South Florida

View Trial →

NCT05786924 Phase 1, Phase 2

Recruiting

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Enrollment

554 pts

Location

United States, Austr...

Sponsor

Institut de Recherches Interna...

View Trial →

NCT06640582 Phase 1, Phase 2

Recruiting

TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas

Contribution of the CEST Sequence in the Characterization of Radionecrosis of Brain Metastases of Pulmonary Origin

Assistance Publique - Hôpitaux...

View Trial →

NCT07481786 Phase 3

Recruiting

Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases

Sun Yat-sen University

View Trial →

NCT07632092

Recruiting

Early [18F]-FDG PET Dynamic Analysis in Brain Metastases After Radiotherapy.

Centre Hospitalier Universitai...

View Trial →

NCT06620380 Phase 2

Recruiting

Ex Vivo Drug Response Evaluation for Next Generation Care of Brain Metastases

Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases

Sun Yat-sen University

View Trial →

NCT02747303 Phase 2

Recruiting

Frameless Stereotactic Radiosurgery for Intact Brain Metastases

University of Chicago

View Trial →

NCT05996432 EARLY_Phase 1

Recruiting

Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy

Vanderbilt-Ingram Cancer Cente...

View Trial →

NCT05987644 Phase 1, Phase 2

Recruiting

Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements

Related Conditions

brain cancer (3) nsclc (3) lung cancer (2) brain metastases adult (2) non small cell lung cancer (2) pancreas cancer (1) renal cancer (1) adrenal metastases (1) prostate cancer (1) liver metastases (1) oligoprogressive nodal metastases (1) metachronous nodal metastases (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology